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Summary 
Although  CD44 is expressed on a wide variety of cell types, few of them use it to recognize 
the ligand hyaluronan (HA). A glycosylation-defective clone of Chinese hamster ovary cells (Lec 
8) bound HA, demonstrating that complete processing of glycoproteins with addition of a full 
complement of sialic  acid is not required.  On the contrary,  subsequent findings revealed that 
complex sugars on CD44 can actually inhibit ligand recognition.  Two subclones of wild-type 
Chinese hamster ovary cells with similar amounts of surface CD44 were isolated on the basis 
of HA binding and found to differ with respect to CD44 size as well as staining with fluorescent 
lectins.  Treatment  of the nonbinding  clone with  tunicamycin reduced the size of the protein 
and allowed the cells to recognize HA via CD44. This function was also induced by treatment 
with deglycosylating enzymes (either a mixture  of endoglycosidase F and N-glycosidase F or 
neuraminidase alone). A possible role for glycosylation in regulation of adhesion was then sought 
with a series of normal and transformed murine cells. Disruption of glycosylation or treatment 
with deglycosylating enzymes did not induce ligand binding in an interleukin 7-dependent pre-B 
cell line,  and splenic B cells also appeared to be in an inactive state. Some normal B cells acquired 
the ability to recognize HA after stimulation with lipopolysaccharide or interleukin 5 and had 
distinctive surface characteristics (loss of immunoglobulin D and acquisition of CD43). An addi- 
tional subset of activated cells might have been in a transitional  state,  because the cells bound 
ligand after neuraminidase treatment.  The ligand-binding ability of a purified CD44-immuno- 
globulin fusion protein dramatically increased after neuraminidase treatment.  Thus, differential 
glycosylation of this molecule is sufficient to influence its recognition function.  Cell adhesion 
involving HA can be regulated by multiple mechanisms, one of which involves variable glycosyl- 
ation of CD44. 
T 
he  adhesiveness  of  immature  blood  cells  must  be 
modulated as they leave the bone marrow and controlled 
thereafter as they interact with vessel walls, cells of the im- 
mune system, and the extraceUular matrix (1). While the den- 
sity of CD44 changes on ceils in bone marrow,  it is more 
dramatically expressed, repressed, and reexpressed as T lym- 
phocytes mature in the thymus (for review see reference 2). 
Levels of CD44 tend to increase with  activation  of B and 
T  lymphocytes,  and  CD44  can be  shed  actively into  the 
circulation by lymphoid and myeloid cells (3, 4). In addition 
to changes in expression and density, other mechanisms may 
regulate the function of this cell adhesion molecule (for re- 
view see reference 2). Although most blood cells are CD44 
positive,  only  small  numbers  use CD44  to  recognize  hy- 
aluronan (HA).1 While resting B cells do not bind HA, ac- 
1Abbreviations used in this paper: CHO, Chinese hamster ovary; endo-E 
endoglycosidase  F; FL-HA, fluorescein-conjugated  HA; HA, hyaluronan; 
MAA, Maacia amurensis; N'ase, neuraminidase; NZB, New Zealand  black; 
NZW, New Zealand white; PNGase-F, N-glycosidase  F; RCA, Ricinus 
communis; SNA,  Sarabucus nigra; UEA1, Utex europaeus; WGA, wheat germ 
agglutinin. 
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tivated B lymphoblasts/plasmacytes do so with high affinity. 
Resting T cells and some cell lines represent an intermediate 
state, in which HA recognition is minimal but can be dra- 
matically augmented by the CD44 mAb IRAWB14.  Days 
are required after stimulation for resting B lymphocytes with 
inactive CD44 to express avid HA receptors (5). The slow 
kinetics of change contrasts with many well-studied integrins, 
whose specificity and avidity for ligands can be rapidly al- 
tered (6). 
The function of CD44 might be regulated by interaction 
with cytoplasmic or surface molecules in the same cell or via 
ligands on opposing cells. This could result in oligomeriza- 
tion of the receptor into high density domains and/or cause 
a change in its conformation. While the amino-terminal por- 
tion of CD44 binds ligand, both transmembrane and cyto- 
plasmic segments are important for determining whether this 
happens on intact ceils (7, 8). Furthermore, there is evidence 
that kinases, lipids, and cytoskeletal components associate with 
CD44 in ways that  might  alter ligand recognition  (9-13). 
Artificial multimerization of CD44 achieved by replacement 
of the transmembrane  segment increased its ability to bind 
HA, and the IRAWB14 mAb was ineffective as a monomeric 
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Fab fragment (8, 14). However, recent analysis of the IRAWB14 
epitope indicates that, in addition to receptor clustering, this 
antibody influences ligand binding by other means (14a). 
Structural heterogeneity in the CD44 protein might also 
account for variations in its ability to recognize HA. Alter- 
native splicing of particular exons can result in an inactive 
molecule (15). However, this may depend on the type of cell 
that expresses it, because the same variant of CD44 is active 
in other situations (16, 17). It is clear that lymphocytes that 
express similar CD44 isoforms can differ with respect to HA 
recognition (2,  18).  We now describe another mechanism 
through which HA binding by CD44 can be regulated. Treat- 
ments that disrupt protein glycosylation lead to increased HA 
recognition in some cell types. Any number of molecules 
might have been altered in those circumstances. However, 
neuraminidase (N'ase) treatment of a purified CD44-Ig fu- 
sion protein resulted in enhanced ability to bind HA. We 
conclude that carbohydrate modification of CD44 limits its 
ability to recognize an abundant natural ligand. These findings 
could increase understanding of the role of CD44 in processes 
such as tumor metastasis, in which HA recognition appears 
to be critical (19).  They also extend studies demonstrating 
that glycoconjugates are important regulators of cell adhe- 
sion mediated by other classes of molecules (20-24). 
Materials and Methods 
Animals.  BALB/c and  New Zealand black  (NZB)  ￿  New 
Zealand white (NZW) F1 mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). 
Cells, Cultures, and Antibodies.  Wild-type Chinese hamster ovary 
(CHO) cells and Lec 8 CHO cells (25) were kindly provided by 
Dr. Richard Cummings (Department of  Biochemistry and Molec- 
ular Biology, University of  Oklahoma Health Science  Center, Okla- 
homa City, OK). CHO/SKN and CHO/SKP were subcloned from 
wild-type CHO cells on the basis of HA recognition. They were 
all cultured in MEM supplemented with 50/~M 2-ME, t-glutamine, 
nonessential amino acids, penicillin, streptomycin, and 10% FCS. 
WEH1231 B lymphoma and L cells were obtained from the Amer- 
ican Type Culture Collection (Rockville, MD) and maintained in 
RPMI 1640 with t-glutamine, 50/~M 2-ME, 10% FCS, and anti- 
biotics. The WB T lymphoma, kindly provided by Dr. Jayne Lesley 
(The Salk Institute, San Diego, CA), was used to derive the WB-N 
subclone. It was maintained in DMEM with 2-ME, L-glutamine, 
10% FCS, and antibiotics. The Ib7-dependent D6 pre-B cell clone 
has not been previously described. It was derived from the bone 
marrow of a bcl-2 transgenic mouse and maintained in supplemented 
RPMI 1640 medium with IL-7. The KMl14 (IgG1) and KM81 
(IgG2a) mAbs recognize both murine and hamster CD44 (14a). 
The IRAWB14 antibody to CD44, which enhances ligand binding 
(7), was originally donated by Dr. Jane Lesley.  The KMI6 (IgG2a) 
mAb (26) to fll integrin was used as an irrelevant isotype-matched 
control. Antibodies used for three-color flow cytometry analysis 
included 14.8-PE (CD45R) obtained from Pharmingen (San Diego, 
CA), $7 (CD43),  which was purified and biotinylated in our lab 
from the hybridoma obtained from American Type Culture Col- 
lection, the 1126C-1 antibody to IgD prepared as described (27), 
rat anti-mouse IgM-FITC (Zymed Laboratories, Inc., South San 
Francisco, CA), rat anti-mouse CD44-FITC (Southern Biotech- 
nology, Inc., Birmingham, AL), and biotinylated rat anti-mouse 
CD3 (GIBCO BRL, Gaithersburg, MD). These were detected with 
Cy-chrome-labeled  streptavidin (Pharmingen) or FITC-streptavidin 
(Zymed Laboratories, Inc.). 
Reagents.  N'ase (from Arthrobacter ureafaciens) and a mixture 
of endoglycosidase F (endo-F) and N-glycosidase F (PNGase-F) 
(from Flavobacterium meningosepticum) were purchased from Sigma 
Chemical Co. (St. Louis, MO). Tunicamycin  was from Calbiochem- 
Novabiochem  Corp.  (La Jolla,  CA).  FITC-conjugated  Maacia 
amurensis lectin (MAA) and Sambucus nigra lectin (SNA) were from 
E-Y Laboratories (San Mateo, CA). SNA staining always dimin- 
ished with N'ase treatment of cells and was used to confirm sialic 
acid release. MAA is actually a mixture of two lectins, which 
differentially recognize complex glycoconjugates (28). While its 
binding to cells decreased with tunicamycin treatment, it reprodu- 
cibly increased after N'ase treatment (see Table 2). FITC-conjugated 
Ulex europaeus (UEA1), Con A, Ricinus communis (RCA120), and 
wheat germ agglutinin (WGA) were purchased from Vector  Labora- 
tories, Inc. (Burlingame, CA). 
Flow Cytometry.  Cells  were stained with fluorescein-conjugated 
HA (FL-HA;  3.5/~g/ml) (7) or FITC-conjugated SNA (20/~g/ml), 
MAA (20/zg/ml),  RCAlz0 (20 #g/ml), UEA1 (20/~g/ml), Con A 
(20/lg/ml), or WGA (10 #g/ml) in FCS/PBS (PBS  containing 5% 
FCS and 0.1% NAN3) for 15 min at 4~  Cells were washed with 
FCS/PBS and analyzed with a FACScan  |  (Becton Dickinson and 
Co., Mountain View, CA). Dead cells were gated out on the basis 
of propidium iodide staining. The CD44 dependence of FL-HA 
staining was always determined by blocking with the CD44-specific 
mAb KMl14 (14a, 29). PE-labeled CD45R and either biotinylated 
CD43 or biotinylated anti-IgD mAb were used with FbHA, fol- 
lowed by Cy-chrome-labeled streptavidin for three-color analyses. 
Cell sorting was carried out on a FACStar  ~u~s~ (Becton Dickinson 
and Co.) using wild-type CHO cells stained with FL-HA. The 5% 
most positive, or least positive, cells were sorted and then cloned 
by limiting dilution to yield the CHO/SKP and CHO/SKN sub- 
clones, respectively. 
Preparation ofsCD44-Ig.  A soluble fusion protein was prepared 
containing the extracellular domain of murine hemopoietic CD44 
and the hinge, CH2, and CH3 regions of human IgGl (CD44-Ig) 
as described previously by others (30). The Ig cassette was gener- 
ously provided by Dr. A. Aruffo (Bristol-Myers, Evansville, IN). 
The CD44-Ig construct was prepared in the pEF-BOS vector and 
transfected into 293T human renal cell carcinoma cells with a stan- 
dard calcium phosphate method (31). Superuatants were harvested 
after 5 d. CD44-Ig was then purified from the culture superna- 
tants with a column of immobilized protein A (Pierce, Rockford, 
IL), and eluted protein was dialyzed against PBS. The concentra- 
tion of  purified CD44-Ig was determined by a CD44-specific  ELISA 
as previously described (4). 
Binding of  HA to Immobilized CD44-Ig.  Dilutions of CD44-Ig 
were agitated with protein A-coated agarose beads (Pierce) for 2 h 
at room temperature. After washing, the coated beads were treated 
with N'ase (1 U/ml) in 50 mM sodium phosphate, pH 6.5, over- 
night at 37~  Controls were treated under identical conditions 
except without N'ase. The CD44-Ig-coated beads were then in- 
cubated with FL-HA for 30 min at 4~  In some experiments, the 
beads were first incubated with anti-CD44  mAb (10/~g) for 15 
min at 4~  and then stained with FIcHA. After a final wash, the 
beads were analyzed with a 400-/~m nozzle on a FACStar  Prvs| 
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not increase their background  binding  to FbHA. 
Immunoprecipitation and Immunoblotting.  Cells  were surface la- 
beled with a biotinylation procedure (27). Live  cells (107/ml) were 
incubated with sulfosuccimidobiotin  (Pierce)  (0.1 rag/m1) in labeling 
buffer (150 #M NaC1, 0.1 M Hepes, pH 8.0) for 30 rain at room 
temperature. Cells were then washed with KPMI 1640 medium 
containing 3% FCS and lysed with 1% Triton X-100 in 10 mM 
Tris, pH 7.5,150 mM NaCI, 3 mM EDTA, 50 mM iodoacetamide, 
0.1%  NAN3, 1 mM PMSF, 10 #g/ml soybean trypsin inhibitor, 
1 #g/m1 leupeptin,  and  1 U/ml aprotinin  for 1 h at 4~  The 
detergent-solubilized materials were recovered after centrifugation 
and precleared with 50 #1 of goat anti-rat IgG Sepharose 4B beads 
(Zymed Laboratories, Inc.) conjugated with irrelevant  control KMI6 
(IgGh) mAb, followed by immunoprecipitation with either KM81 
(IgGh) or KMI6 as a negative control. After extensive washing, 
proteins were eluted from beads by boiling in nonreducing SDS 
sample buffer and analyzed by SDS-PAGE with a 7.5%  gel, fol- 
lowed by transfer to a nitrocellulose membrane (Bio-Rad Labora- 
tories, Hercules, CA).  The membrane was blocked with 0.5% 
gelatin in PBS plus 0.05% Tween 20 and 0.05% thimerosal for 
1 h at room temperature, and it was incubated with 1/5,000 diluted 
streptavidin-horseradish peroxidase  in PBS containing 1% BSA and 
0.05% Tween 20. The protein bands were detected using the en- 
hanced chemiluminescence system (Amersham Corp.,  Arlington 
Heights, IL). Prestained molecular weight markers (Sigma Chem- 
ical Co.) were used as standards. CD44-Ig on the protein A beads 
was untreated or treated with N'ase and then analyzed by SDS- 
PAGE under reducing conditions. After transfer to the membrane, 
CD44-Ig was detected with 1/2,000 diluted horseradish peroxi- 
dase-coupled goat anti-human IgG (Southern Biotechnology, Inc.) 
and the enhanced chemiluminescence system. 
Preparation and Culture of Splenic B Cells.  B cells were prepared 
by treating  spleen cells from 8-12-wk-old BALB/c or (NZB  x 
NZW) F1 mice with anti-Thyl.2 mAb plus complement (Accurate 
Chemical Corp.,  Westbury, NY) as previously described (32). B 
cells from NZB/W F] mice were mainly used because they are 
more sensitive to II.-5 than are those of BALB/c mice (33). The 
B cells (5  x  106/ml) were cultured for 3 d in RPMI 1640 sup- 
plemented with 50 #M 2-ME, penicillin, streptomycin, and 10% 
FCS. Stimulants were LPS (10 #g/ml) or Ib5 (1,000 U/ml)  (a 
generous gift of Dr.  Kiyoshi Takatsu, Tokyo University, Tokyo, 
Japan).  After culture,  >99% of cells were [gM positive. 
Enzyme Treatment.  Cells  (2  x  10  s) were cultured in medium 
with addition of tunicamycin (10 #g/ml) overnight.  They were 
then suspended (2  x  106/ml) in buffered medium (KPMI 1640/ 
PBS, 1:1, pH 6.8) with N'ase (0.4 U/ml) or endo-F/PNGase-F 
(4 U/ml) and incubated for 2 h at 37~  with gentle shaking as 
reported by others (22). The reaction was terminated by washing. 
None of the enzyme treatments influenced cell viability. Control 
cells were treated under identical  conditions, except  without enzyme. 
Statistical Analysis.  The significance of differences was evalu- 
ated by means of paired Student's t tests using the SigmaStat pro- 
gram (Jandel Scientific, San Rafael, CA). 
Results 
HA Recognition by CHO Mutants and Sublines.  CHO cell 
mutants and sublines have long been exploited for study of 
protein glycosylation (34-36), and we hoped they would be 
informative about CD44-mediated recognition of HA. In pre  ~ 
liminary experiments, we screened a number of them and 
found variations in their ability to bind FL,  HA. Strong CD44- 
mediated recognition of HA was observed with mutant Lec 
8 cells, but there was heterogeneity of binding with wild- 
type CHO cells (Fig. 1 and data not shown). The latter were 
sorted and cloned on the basis of HA recognition, yielding 
two subclones (SKP and SKN), which differed for this prop- 
erty but had similar amounts of cell surface CD44 (Fig.  1). 
Fluorescent lectins were used to explore the possibility that 
the subdones might differ with respect to glycosylation (Table 
1 and data not shown). The most significant difference was 
with the RCA lectin, which gave an average of 5.8-fold higher 
staining with the HA-nonbinding CHO/SKN subdone than 
with the HA-binding CHO/SKP subclone (P =  0.0001) in 
eight independent experiments. Significant differences of less 
magnitude were obtained with WGA and MAA lectin (P 
=  0.0002 and 0.0004, respectively). The two subdones were 
similar with respect to staining by fluorescent Con A (P = 
0.578). Lectins also confirmed that the Lec 8 cells were defective 
in glycosylation, as this mutant exhibited virtually no staining 
with either MAA or RCA (2 and 8% of wild-type values, 
respectively). 
Lec 8 cells have been well characterized and are known to 
express incompletely glycosylated proteins (37). There is an 
inability to transport uridine diphosphate galactose from the 
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Figure  1.  CHO cell lines differ  in ability to recognize  HA via CD44. 
The glycosylation-defective  Lec 8 clone  of CHO cells is compared  with 
two subdones of wild-type CHO cells, which were sorted on the basis 
of HA recognition.  Levels  of CD44 were demonstrated  by staining with 
biotinylated anti-CD44 mAb (KMl14) followed  by FITC-labeled  strep- 
tavidin. Ligand  binding was analyzed  by exposure  of cells to FDHA. To 
investigate  CD44 dependence  of HA recognition,  calls were  preincubated 
with unlabeled  KMll4 before  staining  with FL-HA.  All samples were  then 
analyzed by flow cytometry. 
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Differences in  CHO Cell Subclones 
Lectin  CHO/SKN  CHO/SKP 
UEA1  5  _+  1  4  +  1 
Con A  35  +  20  40  +  29 
RCA120  619  _+  196  107  +  39* 
WGA  1489  _+  377  1104  _+  384* 
MAA  214  _+  62  127  _+  34* 
Cells were stained with FITC-labeled  UEA1, Con A, RCA120, WGA, 
or MAA and analyzed  by flow  cytometry.  The values represent mean _+ 
SD median fluorescence  intensities of eight independent experiments. 
* Highly significant differences (KCA120, P  =  0.0001; WGA, P  = 
0.0002; MAA, P  =  0.0004). 
cytosol to the Golgi, resulting in proteins lacking galactose. 
The majority of sialic acids on cell surface glycoconjugates 
are linked to galactose,  and, consequently, Lec 8 cells have 
markedly reduced cell surface sialic acid. Our findings dem- 
onstrate that expression of such mature, complex sugars is 
not required for CD44-mediated recognition of HA (Fig. 1). 
Furthermore, subclones of wild-type CHO cells, which differ 
with respect  to HA binding, also differ in staining by three 
lectins. These findings indicated that certain protein glycosyl- 
ation patterns may negatively influence the ability of cells 
to recognize HA via CD44. 
Reductions in Glycosylation Increase HA Recognition by CHO 
Cells.  The wild-type subclone of CHO cells that failed to 
recognize HA (CHO/SKN) was then exposed to tunicamycin 
overnight to disrupt N-linked glycosylation (38) under treat- 
ment  conditions  that  had  no  influence on  cell  viability. 
Decreased  staining with fluorescent KCA confirmed that 
glycosylation was affected. The density of cell surface CD44 
as detected with the KMl14 antibody was reduced on av- 
erage by 32% (median fluorescence intensity, Fig. 2). Similar 
results were obtained with the KM81 antibody, which has 
similar specificity to KMll4 (14a). Reduced transport of pro- 
tein to the cell surface and/or partial loss of an epitope may 
account for the reduced staining with this antibody. Indeed, 
recognition of hamster cells by the KM201 antibody to mu- 
rine CD44 was virtually abolished by tunicamycin treatment 
(data not shown). 
In contrast to the apparent decrease in cell surface CD44, 
there was a dramatic increase in the ability of treated CHO/ 
SKN cells to recognize FL-HA. In three experiments, treated 
cells bound ligand an average of 6.8-fold better than control 
cells.  This  binding  was  CD44  mediated  and  completely 
blocked by the KMl14 mAb (Fig.  2). 
Cell surface labeling and immunoprecipitation were then 
used to evaluate the glycosylation status of CD44 on CHO 
cell subclones and treated cells. The principal species of CD44 
in Lec 8 cells was ",~70 kD in size and clearly smaller than 
the corresponding bands in wild-type subclones  (Fig. 3 A). 
A small, but consistent, difference in CD44 size was found 
between the two subclones.  We estimate that CD44 immu- 
noprecipitated from the HA-binding subclone (CHO/SKP) 
was  ",,4  kD  smaller  than  that  obtained  from  the  HA- 
nonbinding subclone (CHO/SKN). Tunicamycin treatment 
always generated a very small (~,58  kD) species of cell sur- 
face CD44 (Fig.  3 B), and, in some experiments, virtually 
all of the CD44 was converted to this reduced size. 
Enzyme treatments were then used to evaluate the rela- 
tionship between protein glycosylation and HA recognition. 
In two experiments, treatment of the non-HA-binding sub- 
clone (CHO/SKN)  with the combination of endo-F and 
PNGase-F significantly increased ligand recognition (Fig. 4). 
An even more dramatic increase followed treatment of cells 
with A.  ureafaciens N'ase.  Neither of these treatments in- 
fluenced cell viability, and HA recognition was completely 
CD44 mediated (data not shown). Furthermore, the influence 
of these enzymes on cell surface glycoproteins was confirmed 
by staining with fluorescent lectins RCA and MAA (Fig. 
4). Staining with RCA reproducibly decreased while that with  MAA  increased. The latter is actually a mixture of two lectins 
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Figure  2.  Tunicamycin  treatment  induces HA recog- 
nition on a nonbinding  subclone  of CHO cells. Cells  were 
incubated  with or without tunicamycin  (10 #g/ml) over- 
night at 37~  which resulted in a slight loss of CD44 
as detected  with biotinylated  KMll4. Ligand  binding  was 
assessed with FL-HA  and CD44 specificity  by preincuba- 
tion with unlabeled  KMll4 antibody.  The FITC-labeled 
KCA lectin  was used to assess changes  in cell surface  gly- 
coproteins. All cells were analyzed  by flow cytometry. 
422  CD44  Glycosylation  and Function Figure  3.  Sizes  of CD44 on CHO cell subclones. (A) Cells were sur- 
face labeled with biotin  and lysed with  Triton X-100. Extracts were 
precleared and immunoprecipitated  with anti-CD44  mAb (KM81)  or control 
mAb (KMI6). (B) HA-nonbinding CHO cells (CHO/SKN)  were cul- 
tured with or without  tunicamycin (10 #g/ml) overnight at 37~  and 
surface labeled with biotin. Triton X-100 extracts were immunoprecipi- 
tared as described above. Samples were analyzed by SDS-PAGE (7.5%) 
under nonreducing conditions and visualized as described  in Materials and 
Methods. 
with complex specificity for glycoproteins (28),  and we as- 
sume that  cryptic binding sites were exposed by release  of 
terminal sialic acids. All of these observations would be con- 
sistent  with a negative regulatory role for glycosylation on 
CD44-mediated  HA recognition in  CHO  cells. 
N'ase Treatment Increases HA Recognition by Particular  Lym- 
phoma Cells.  Previous studies revealed that lymphoid cells 
can be divided into categories with respect to HA recogni- 
tion (2). One type of cells, typified by resting splenic B cells, 
or an IL-7-dependent pre-B cell clone (D6),  does not bind 
HA and is unaffected by the enhancing IRAWB14 mAb. We 
found that  neither  N'ase treatment  of either  cell  type nor 
tunicamycin treatment  of the pre-B cell line influenced the 
ability of these  cells  to  bind  HA  (Table  2).  Staining  with 
fluorescent lectins confirmed that glycoproteins were modified 
by these manipulations.  Investigation of possible effects of 
tunicamycin on nonstimulated spleen cells was not possible 
because of poor cell viability. We also tested a fibroblast cell 
line  (L cells),  which has only partial  responsiveness  to  the 
IRAWB14 antibody (results not shown), and we found that 
Table  2.  Effect  of Deglycosylation on HA Recognition 
Median fluorescence 
intensity 
KMl14 
Cells  Treatment  CD44  HA  +  HA 
Splenic  B  Control  52  5  5 
N'ase  60  9  10 
D6 
L  cell 
WB-N 
W231 
Control  81  5  6 
Tunicamycin  54  3  3 
Control  70  5  6 
N'ase  96  5  6 
Control  60  2  2 
Tunicamycin  20  7  3 
Control  87  2  2 
N'ase  78  7  2 
Control  109  11  6 
Tunicamycin  116  46  5 
Control  111  15  4 
N'ase  129  41  5 
Control  149  10  4 
Tunicamycin  75  31  4 
Control  107  15  2 
N'ase  104  30  2 
Cells were treated with tunicamycin or N'ase and stained with FL-HA, 
SNA, MAA, or biotinylated KMl14 plus FITC-streptavidin before flow 
cytometry analysis. As a specificity  control, cells were stained with FL- 
HA after incubation with KMl14.  The values represent median fluores- 
cent intensities after subtraction of background fluorescence. Represen- 
tative results were from one of two to three similar experiments. The 
first three cell types failed to bind HA in the presence of IRAWB14, 
but the other two cell lines were able to bind HA after incubation with 
IRAWB14. 
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Figure 4.  Enzymatic  deglycosylation  increases HA rec- 
ognition  by CHO  cells. HA-nonbinding CHO  cells 
(CHO/SKN)  were treated with  endo-F/PNGase-F or 
N'ase as described in Materials and Methods. They were 
then stained with FL-labeled  ligand (HA) or either FITC- 
labeled RCA or MAA lectins before being analyzed by 
flow cytometry. they were very slightly  influenced  by treatment  with  tu- 
nicamycin or N'ase (Table 2). 
￿9  Another category of cells, typified by certain lymphomas 
and resting T lymphocytes, does not constitutively bind HA 
but does so in the presence of the enhancing IRAWB 14 an- 
tibody (2, 7). The WEHI 231 B lymphoma and the WB-N 
T  lymphoma line have these properties,  and we now show 
that they are similar to CHO cells in that they are responsive 
to deglycosylation (Table 2). This was true even in experi- 
ments in which tunicamycyin treatment  markedly reduced 
cell surface CD44  density (Table  2).  All examples  of HA 
binding were CD44 mediated and completely sensitive to the 
blocking KMl14 antibody. These results reveal that glycosyl- 
ation may represent one mechanism for negative regulation 
of HA recognition by certain CD44-bearing cells. However, 
there must be additional mechanisms for controlling this pro- 
cess, because some CD44-bearing  cells remained unable to 
bind ligand  under  the same treatment  conditions. 
Characteristics of Activated  B  Cells  That  Can  Recognize 
HA.  While normal resting B cells do not bind HA, activa- 
tion that  accompanies mild graft-versus-host disease or ex- 
posure to IL-5 produces a small subpopulation of lympho- 
cytes that  has  this  capability  (5,  39,  40).  Several  days  are 
required for this change,  which correlates with a subtle change 
in glycosylation of CD44 (40). We have now extended those 
findings by use of three-color flow cytometry, which revealed 
that HA-binding B cells were induced to express the CD43 
antigen  (Fig.  5, A  and B, depicts LPS- or Ib5-activated B 
cells, respectively). All cells with high levels of CD44 were 
also positive for CD43.  A  selective loss of IgD  represents 
an additional property of HA-binding B cells (Fig.  5).  The 
transition  of resting  B  cells  (small  in  size,  IgM +,  IgD § 
CD43-,  CD44  l~  that  did not recognize HA to fully acti- 
vated cells  (large  in  size,  IgM +,  IgD-,  CD43 § ,  CD44 hi) 
corresponded to the appearance of HA-binding lymphocytes. 
This was true regardless of whether LPS (Fig.  5 A) or Ib5 
(Fig.  5 B) was used as an activation stimulus. However, HA- 
binding lymphocytes still only represented a subpopulation 
of activated B cells. These studies demonstrate that cell sur- 
face markers  can be used to identify activated lymphocyte 
populations that include those that have acquired the ability 
to bind HA. A fraction of activated cells with similar surface 
characteristics  still did not recognize this ligand. 
A  Subset  of Activated  B  Cells  May  Be  in  a  Transitional 
State.  We then explored the possibility that glycosylation 
contributes to the inability of some partially activated B cells 
to recognize HA.  Indeed,  when  splenic B cells  were acti- 
vated with either LPS or IL-5, twice as many bound HA after 
an additional treatment with N'ase (Table 3). This increase 
in numbers of HA-binding cells was not accompanied by an 
increase in the amount of ligand bound per cell, and there 
was no influence of treatment on CD44 density (as reflected 
by median channel numbers). Again, all HA recognition was 
CD44 mediated. We conclude that the glycosylation status 
of some cell surface protein(s) on a subset of activated B lym- 
phocytes negatively influences their ability to recognize HA. 
This contrasts with resting B cells that were not induced to 
bind ligand  by this  single treatment  (Table  1). 
Removal of Sialic  Acid Increases HA Recognition by a CD44-Ig 
Fusion Protein.  Multiple cell surface proteins are influenced 
by treatments that inhibit or reverse glycosylation events, and 
it was unclear whether carbohydrate modification of CD44, 
or some other protein, influenced its ligand-binding ability. 
Therefore,  we prepared a soluble fusion protein consisting 
of the extracellular portion of murine hemopoietic CD44 with 
the hinge,  CH2,  and CH3 domains of human  IgGt.  This 
approach has been extensively used by others to investigate 
the intrinsic HA recognition potential of human CD44 (15, 
30, 41). Graded amounts of the purified fusion protein were 
adsorbed to protein A-conjugated Sepharose beads, which 
were washed before exposure to a constant amount of fluores- 
cent HA (Fig.  6 A).  The resulting binding,  as assessed by 
flow cytometry, was CD44 specific and completely blocked 
by treatment with the monoclonal KMl14 antibody (Table 
4). Pretreatment  of the CD44-Ig-coated beads with N'ase 
increased their ability to recognize HA up to sevenfold, while 
enzymatic treatment  of uncoated control beads did not re- 
sult in binding. The enhancing effect of N'ase treatment on 
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Figure 5.  Characteristics  of HA-binding B cells after 
activation in culture. T cell-depleted splenic  B cells from 
NZB/W F1 mice were cultured with LPS (10/~g/ml) (.4) 
or 1I.-5 (1,000 U/ml) (B) for 3 d before  analysis by three- 
color flow  cytometry.  All contour plots were obtained  by 
gating on CD45R§ cells. The left panels demonstrate 
ligand (HA)-binding  cells and their expression  of the CD43 
antigen. The middle panel analyzes dual expression of 
CD43 and CD44 antigens. The right panel demonstrates 
that all HA-binding cells have  lost the IgD isotype  of Ig; 
however, they were still IgM positive  (not shown). These 
results are typical of those obtained in three independent 
experiments. Table 3.  Effect  of Deglycosylation on HA  Recognition by Activated Splenic B  Cells 
Treatment  HA  CD44  KMl14 + HA  SNA 
% 
Positive  MFI  MFI  MFI  MFI 
LPS  7.6  _+  0.7  26  _+  3  51  _+  5  1  +  0  52  _+  13 
LPS+N'ase  18.1  _+  1.2  30  +  3  57  _+  3  1  _+  0  9  _+  2 
IL-5  5.9  _+  1.2  52  -+  12  38  -+  1  1  _+  0  35  -+  6 
IL-5+N'ase  12.1  +  2.8  46  _+  7  38  _+  3  1  _+  0  6  _+  1 
T cell-depleted splenic cells were cultured with LPS (10/~g/ml) or IL-5 (1,000 U/ml) and treated with N'ase as described in Materials and Methods. 
The cells were then tested for HA binding by flow cytometry after staining with FL-HA. As a specificity control, cells were also incubated with 
the blocking antibody, KM114, followed by staining with FITC-HA. The values represent means _+  SD percent HA-binding cells and/or median 
fluorescence intensities (MFI). 
HA recognition was  similar  in  three  separate  experiments 
and where fluorescent HA was used over a 100-fold concen- 
tration range (average of 3.6-fold increase). We recovered the 
CD44-Ig from control and N'ase beads and analyzed it by 
SDS-PAGE under reducing conditions (Fig. 6 B). Enzymatic 
treatment  reduced the size and heterogeneity of the fusion 
protein. 
The IRAWB14 antibody has been shown to markedly in- 
crease HA recognition  on particular  types of lymphocytes 
(2,  7,  14).  We now  show  that  it  also has  this  effect  on a 
CD44-Ig fusion protein  immobilized on beads,  regardless 
of whether the protein had been N'ase treated (Table 4). We 
conclude from these experiments  that  terminal  sialic acids 
diminish the intrinsic HA-recognizing capability of CD44. 
The strong enhancing effect of the IRAWB14 antibody sug- 
gests that conformational changes in CD44 may also influence 
its  function. 
Discussion 
CD44 is subject to enormous molecular diversity. We now 
show  that  changes  in  glycosylation  status  can  markedly 
influence ligand recognition. Treatments that altered glycosyl- 
ation in whole cells or purified CD44 significantly increased 
binding to HA. There is precedent for these findings with 
other cell adhesion molecules. This might be regarded as but 
one relatively slow mechanism through which cells can regulate 
adhesiveness. 
Lymphoma subdones have been described that differ with 
respect to HA binding but are similar in terms of the number 
Figure  6.  Desialylation of a CD44 containing fusion protein increases 
HA recognition. (A) Protein A-bearing beads were loaded with graded 
amounts of  CD44-Ig, and 1 aliquot of  each sample  was treated with N'ase. 
The beads were then tested for HA-binding ability by flow cytometry. 
The results are shown as means _+ SD. MFI, median fluorescence  inten- 
sity. (B) CD44 was then extracted from similarly treated beads by boiling 
in SDS-PAGE  buffer under reducing conditions. This material was ana- 
lyzed by SDS-PAGE  and Western blotting. The mobility of size standards 
is indicated. 
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Table 4.  CD44-specific  Antibodies Influence HA Recognition by 
a CiM4-Ig Fusion Protein Immobilized on Beads 
Untreated  N'ase-treated 
Antibody treatment  beads  beads 
Control  113  493 
KMl14  7  7 
IRAWB14  3,162  2,839 
CD44-Ig-coated beads were treated with N'ase and stained with FL-HA 
after incubation with anti-CD44 mAbs, KMl14, or IRAWB14 (10/~g) 
for 15 min at 4~  HA-binding ability was evaluated by flow cytome- 
try. Values represent median fluorescence  intensities from one of two simi- 
lar experiments. and sizes of CD44 molecules (2, 18). It has been suggested 
that local densities of CD44 on the membrane and/or con- 
formational changes might partially explain differences  in HA 
recognition between such cells (8, 14). Either type of  change 
in CD44 would be regulated through interaction with other 
molecules, and there is evidence that both the transmembrane 
and cytoplasmic domains of CD44 are important (7, 8). Fur- 
thermore, palmitoylation or reversible  phosphorylation of the 
molecule might result in dynamic associations with other 
molecules (9,  11-13, 42). 
Heterogeneity  in the structure of CD44 might also deter- 
mine its ability to recognize HA. It has been demonstrated 
that one "epithelial" isoform of human CD44, which includes 
an exon product not commonly  used by blood ceils, had greatly 
reduced HA-binding ability (15). However, this might de- 
pend on the type of cell that expresses this alternately spliced 
CD44 isoform, because the murine homologue and even the 
human isoform bind HA in other circumstances (16, 17). As 
another example of structure/function heterogeneity,  addi- 
tion of chondroitin sulfate and heparan sulfate to the protein 
confers the ability to recognize the additional  ligands col- 
lagen and fibronectin  (43). 
The core protein of CD44 is predicted to be only 42 kD, 
but it has at least five motifs for asparagine-linked carbohy- 
drate attachment and 10 possible sites for O-linked glycosyl- 
ation (44). The mature protein on most blood ceils is ,,o90 
kD, and the acidic charge (isoelectric point  =  4.2) is largely 
contributed by sialic acids (45, and for review see reference 
2). A number of studies have used enzymatic treatments to 
conclude that multiple carbohydrate modifications are differen- 
tially used by various cell types to diversify the structure of 
this protein (45-48). Purr and co-workers demonstrated that 
the CD44 on resting and activated macrophages differed not 
only with respect to phosphorylation and cytoskeletal associ- 
ation, but also in the degree of N-glycosylation (42). More 
recently, the CD44 on B lymphocytes was found to be slightly 
smaller after IL-5 activation, and the difference was lost after 
PNGase-F treatment (40). Carbohydrate side chains on CD44 
can be recognized as blood group antigens, and it has been 
speculated that fucosylation might modulate functions of the 
molecule associated with the tumorigenicity of colon carci- 
noma cells (49). 
Bourguignon and co-workers (47) reported that the smallest 
biosynthetic precursor of CD44 was unable to bind HA and 
that this  function was acquired with addition of O- and 
N-linked sugars. We found that CD44 on the Lec 8 mutant 
of CHO cells avidly bound HA (Fig. I). These cells are un- 
able to transport uridine diphosphate galactose to the Golgi, 
resulting in  incompletely glycosylated  proteins  (37). We 
confirmed that the major CD44 was of reduced size (Fig. 
3). Therefore, while the HA-binding function might be ac- 
quired simultaneously with a minimum amount of carbohy- 
drate during biosynthesis, complete processing is not required. 
It will be important to determine why the ligand recogni- 
tion function of CD44 is increased after N'ase treatment. The 
overall charge of the glycoprotein could be important, and 
sialic acids might interfere with cooperation between clustered 
molecules. Alternatively, carbohydrate might contribute in 
a positive or negative way to the actual ligand-binding  site. 
In this context, it is interesting that the cross-reactivity of 
the KM201 antibody for hamster cells was completely lost 
by treatment with tunicamycin. This reagent has been used 
to block HA recognition by a variety of cell types in mice 
and humans (14a, 29, 50). Its epitope might therefore be close 
to the HA-binding region. 
Carbohydrates constitute important ligands for members 
of the selectin family of cell adhesion molecules (36, 51-53). 
CD22 and sialoadhesin are two recently described proteins 
whose ligand specificity is sialic acid dependent (21). In addi- 
tion, there are examples where the functions ofintegrins and 
Ig superfamily members may be influenced by glycosylation. 
N-linked glycosylation is reportedly essential for association 
of the Oes/31 integrin subunit chains as well as for recogni- 
tion  of the ligand fibronectin  (22). On  the other hand, 
N-linked side chains  of intracellular  adhesion molecule  1 
(CD54) diminish its recognition by the CDllb/CD18 inte- 
grin (23). Furthermore, extensive sialylation of neural cell 
adhesion molecule acts as a negative regulator of adhesion, 
possibly by reducing homophilic recognition (24). 
While integrin-dependent adhesiveness  of cells can change 
rapidly (6, 54, 55), days are required to observe changes in 
the ability of stimulated lymphocytes to bind HA (5, 56). 
It has previously been demonstrated that either IL-5 stimula- 
tion or a graft-versus-host response generates a subpopula- 
tion of B lymphocytes that can bind HA (5, 39, 40). There 
was a corresponding increase in the size of the lymphocytes, 
as well as in the average density of CD44 and IgM, while 
CD45R expression decreased. As noted above, the degree of 
N-linked glycosylation of CD44 was also slightly less on ac- 
tivated cells (40). We now demonstrate two additional changes 
and show that LPS stimulation gives similar results to those 
that occur with IL-5 stimulation.  HA-binding lymphocytes 
appeared in culture by 3 d after IL-5 or LPS addition.  All 
of them had lost IgD and acquired CD43 (as recognized by 
the $7 mAb, Fig. 5). The latter marker is interesting in that 
it may share with CD44 the ability to associate  with the ERM 
family of cytoskeletal proteins (10, 57). Like CD44, it is shed 
from the surface of activated cells, and it loses some sialic 
acid when lymphocytes become activated (58, 59). Further- 
more, it has been reported that CD43 might interfere with 
interactions between the CDllb/CD18 integrin and intra- 
cellular adhesion molecule 1 (60). Moreover, N'ase treatment 
diminished  the CD43 antiadhesive effect. We know of no 
evidence for physical association or functional cooperation 
between CD43 and CD44.  It remains to be determined if 
it is mere coincidence that CD43 is acquired on cells that 
become able to use CD44.  Among activated B cells, two 
subsets of approximately equal number were recognized. One 
constitutively bound HA, and the other did so after N'ase 
treatment. 
The glycosylation status of CD44 could be important for 
regulating its roles in a wide range of biological processes 
(2). N'ase treatment of endothelial cells decreases lympho- 
cyte attachment, while treatment of lymphocytes can increase 
the same interactions  (61, 62). These observations were in 
part attributable to selectin ligands, but they demonstrate the 
426  CD44  Glycosylation  and Function importance of glycoconjugates to lymphocyte migration pat- 
terns. Interestingly, terminal sialic acid residues on glycopro- 
teins may inhibit the ability of resting B  lymphocytes to 
conjugate with T cells, present antigens, and function as stimu- 
lators in mixed lymphocyte responses  (63).  Furthermore, it 
has been suggested that endogenous sialidase activity may 
contribute to the ability of activated B cells to effectively in- 
teract with T lymphocytes (64). Terminal sialic acids on CD44 
diminish its HA recognition function, and it will be impor- 
tant to learn if this influences its interaction with other pos- 
sible ligands (43,  65). 
We found that disrupting glycosylation in resting B cells 
or pre-B cells was not sufficient to cause HA recognition, 
suggesting that additional regulatory mechanisms might be 
involved. This point was explored in recent independent studies 
conducted by Lesley et  al.  (66),  who also  found that the 
glycosylation status of cells correlates  with their ability to 
recognize HA via CD44. Their analysis of variant subclones 
demonstrated that multiple steps are required for cells with 
no HA-binding ability to become constitutively active for 
this function. Additionally, one of these steps might involve 
proteoglycan side chains, because treatment of inactive cells 
with B-D-xyloside or chondroitinase ABC to disrupt or re- 
move glycosarninoglycan chains converted cells to a stage where 
they were responsive  to the IRAWB14 antibody. 
These observations raise a number of interesting questions. 
It will be important to determine precisely which carbohy- 
drate modifications control cell interactions via CD44. Changes 
in CD44 structure might then be attributed to particular bio- 
synthetic and/or deglycosylation enzymes, whose expression 
is linked to signals  from the microenvironment. 
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